Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
BCG Oncology, Phoenix, Arizona Stanford University, Stanford, California Rush University Medical Cneter, Chicago, Illinois Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana University of Iowa Hospitals and Clinics, Iowa City, Iowa Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland Dana-Farber Cancer Institute, Boston, Massachusetts Washington University School of Medicine, St Louis, Missouri University of Nebraska Medical Center, Omaha, Nebraska Columbia University Irving Medical Center, New York, New York University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Fox Chase Cancer Center, Philadelphia, Pennsylvania